Evidence map›Paper›PMID 35212881›Full record

ArticleClinical and experimental nephrology2022

Hsp70 promotes maturation of uromodulin mutants that cause familial juvenile hyperuricemic nephropathy and suppresses cellular damage.

Sulistiyati Bayu Utami, Ryo Endo, Toshihiro Hamada, Tomomi Notsu, Hiroyuki Minato, Koji Komatsu, Yuji Nakayama, Yasuaki Shirayoshi, Kazuhiro Yamamoto, Shinichi Okada and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Sulistiyati Bayu Utami *Department of Genetic Medicine and Regenerative Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan.
Ryo Endo *Department of Anesthesiology, Faculty of Medicine, Tottori University, Yonago, Japan.
Toshihiro HamadaDepartment of Community-Based Family Medicine, Faculty of Medicine, Tottori University, Yonago, Japan. thamada@tottori-u.ac.jp.ORCID http://orcid.org/0000-0003-1935-9315
Tomomi NotsuDepartment of Genetic Medicine and Regenerative Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan.
Hiroyuki MinatoDepartment of Anesthesiology, Faculty of Medicine, Tottori University, Yonago, Japan.
Koji KomatsuDepartment of Psychiatry, Faculty of Medicine, Tottori University, Yonago, Japan.
Yuji NakayamaResearch Center for Bioscience and Technology, Tottori University, Yonago, Japan.
Yasuaki ShirayoshiDepartment of Genetic Medicine and Regenerative Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan.
Kazuhiro YamamotoDivision of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Yonago, 683-8503, Japan.
Shinichi OkadaDepartment of Pediatrics, Yonago Medical Center, Yonago, Japan.
Haruaki NinomiyaDepartment of Biological Regulation, Faculty of Medicine, Tottori University, Yonago, Japan.
Akihiro OtukiDepartment of Anesthesiology, Faculty of Medicine, Tottori University, Yonago, Japan.
Ichiro HisatomeDepartment of Genetic Medicine and Regenerative Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan.
Tottori University · JPNational Institute of Technology, Yonago College · JPDiponegoro University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFamilial juvenile hyperuricemic nephropathy (FJHN) is an autosomal dominant disorder caused by mutations in UMOD. Here we studied effects of genetic expression and pharmacological induction of Hsp70 on the UMOD mutants C112Y and C217G.

methodsWe expressed wild type (WT), C112Y and C217G in HEK293 cells and studied their maturation and cellular damage using western blot and flow cytometry.

resultsExpression of C112Y or C217G increased pro-apoptotic proteins, decreased anti-apoptotic proteins, and induced cellular apoptosis as examined by annexin V staining and flow cytometry. Overexpression of Hsp70 or administration of an Hsp70 inducer geranylgeranylacetone (GGA) promoted maturation of the mutant proteins, increased their secreted forms, normalized the levels of pro- and anti-apoptotic proteins and suppressed apoptosis.

conclusionThese findings indicated that Hsp70 enhanced maturation of C112Y and C217G and reduced cellular apoptosis, suggesting that Hsp70 induction might be of a therapeutic value for treatment of FJHN.

Indexed as

HyperuricemiaApoptosis Regulatory ProteinsGoutHEK293 CellsHumansKidney DiseasesPedigreeUromodulinApoptosis Regulatory ProteinsUromodulinApoptosisFJHNGGAHsp70Uromodulin

Identifiers

PMID35212881
OpenAlexW4214734075

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.